BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Graviti Pharma accelerates India expansion with launch of Karnataka operations

23 April 2026 | News

To further strengthen its presence across India



Graviti Pharmaceuticals, a Hyderabad-based pharmaceutical company with a strong and growing presence in international markets, has announced the launch of its operations in Karnataka.

Building on the successful completion of one year of operations in Andhra Pradesh and Telangana, Graviti Pharmaceuticals is now expanding into Karnataka as part of its next phase of growth, reinforcing its ambition to emerge as a leading, quality-driven pharmaceutical player in India.

Headquartered in Hyderabad, the company has established a robust foundation backed by its international business operations, particularly in the United States, and a strong focus on globally benchmarked quality and compliance systems.

Graviti's manufacturing facility at Pashamylaram, Hyderabad, operates in alignment with USFDA standards, reflecting the company's commitment to delivering pharmaceutical products that meet stringent global benchmarks across quality, safety, and regulatory compliance.

Under the leadership of its Managing Director, Dheeraj Gorukanti, and Chief Operating Officer, Thilak Vangala, Graviti Pharmaceuticals continues to strengthen its strategic vision and operational excellence across markets.

Speaking on the occasion, Thilak Vangala, Chief Operating Officer, Graviti Pharmaceuticals, said, "Our entry into Karnataka represents a strategic milestone in our India growth journey. With a strong foundation in international markets and a continued focus on quality and compliance, we are committed to scaling our presence and delivering globally aligned pharmaceutical solutions across key therapy segments."

With this expansion, Graviti Pharmaceuticals aims to further strengthen its presence across India, while continuing to build a scalable, high-quality pharmaceutical platform aligned with global standards and long-term growth ambitions.